8-K: Applied Therapeutics Q3 2025: Reduced Loss, Regulatory Hurdles

Applied Therapeutics reported a significantly reduced net loss in Q3 2025, alongside ongoing regulatory discussions for govorestat in rare diseases and a board leadership change.

Summary

• Reported Q3 2025 financial results, including a net loss of $19.0 million, a significant reduction from $68.6 million in Q3 2024.
• Cash and cash equivalents decreased to $11.9 million as of September 30, 2025, from $79.4 million at December 31, 2024.
• Received Type C meeting minutes from the FDA regarding govorestat for CMT-SORD, with key open issues identified for a potential NDA submission.
• Plans to submit a request for an additional Type C meeting with the FDA to further discuss a potential Phase 3 trial design for CMT-SORD.
• A meeting is scheduled with the FDA in Q4 2025 to discuss the regulatory path forward for govorestat for Classic Galactosemia, following a Complete Response Letter and warning letter issued in November 2024.
• New data from a single-patient investigator-initiated trial for govorestat in PMM2-CDG showed the treatment was well tolerated, a dose-dependent decrease in whole blood sorbitol, and a 46% improvement in the NPCRS score.
• John H. Johnson resigned as Executive Chairman and a director of the Board, effective November 9, 2025, for personal reasons and not due to any disagreement.

Sentiment

Score: 3

Explanation: While the company reported a reduced net loss and some positive clinical data for PMM2-CDG, the significant cash burn and ongoing, complex regulatory hurdles for its lead drug candidate govorestat in its primary indications (CMT-SORD and Classic Galactosemia, the latter having received a CRL and warning letter) present substantial challenges and uncertainty. The need for further FDA meetings without a clear path forward for NDA submission for CMT-SORD, combined with dwindling cash reserves, indicates a precarious financial and operational position.

Positives

• Net loss significantly reduced to $19.0 million in Q3 2025 from $68.6 million in Q3 2024.
• Net loss per share improved to $0.13 in Q3 2025 from $0.48 in Q3 2024.
• Research and development expenses decreased by $5.2 million to $9.6 million in Q3 2025.
• General and administrative expenses decreased by $6.9 million to $8.2 million in Q3 2025.
• Positive results from a single-patient trial of govorestat for PMM2-CDG, showing good tolerability, a dose-dependent decrease in sorbitol, and a 46% improvement in the NPCRS score.
• Govorestat has a robust safety profile, with numerous patients across rare disease indications remaining on treatment for over four years.
• Govorestat has received Orphan Drug Designation and Rare Pediatric Disease designation from the FDA for PMM2-CDG.

Negatives

• Cash and cash equivalents significantly decreased to $11.9 million as of September 30, 2025, from $79.4 million at December 31, 2024, indicating substantial cash burn.
• Regulatory path for govorestat in CMT-SORD faces "key open issues" with the FDA, including conclusive evidence for pathophysiology, use of sorbitol levels as a surrogate endpoint, primary endpoint selection for a potential Phase 3 trial, and carcinogenicity testing.
• The company has not yet determined the specific path forward for regulatory approval for CMT-SORD, including whether an accelerated approval pathway would be pursued.
• The regulatory path for Classic Galactosemia is a follow-up to a Complete Response Letter (CRL) and warning letter issued by the FDA in November 2024, indicating previous setbacks.

Risks

• Uncertainty regarding the regulatory strategy and potential requirements for a New Drug Application (NDA) submission for govorestat for CMT-SORD, including the need for conclusive evidence for pathophysiology, validation of sorbitol levels as a surrogate endpoint, selection of a primary endpoint for a potential Phase 3 trial, and carcinogenicity testing.
• The company has not determined the specific path forward for regulatory approval for govorestat in CMT-SORD, including whether a future NDA submission would be made under the accelerated approval pathway, which could impact approval timelines.
• The regulatory path for govorestat for Classic Galactosemia is a follow-up to a Complete Response Letter (CRL) and warning letter issued by the FDA in November 2024, indicating significant prior regulatory hurdles and uncertainty for future approval.
• Substantial cash burn, with cash and cash equivalents decreasing from $79.4 million at December 31, 2024, to $11.9 million at September 30, 2025, raising concerns about liquidity and the need for additional financing.
• The forward-looking statements section highlights risks related to the initiation, timing, progress, and results of clinical trials, ability to take advantage of expedited regulatory pathways, estimates regarding expenses and capital requirements, ability to obtain and timing of regulatory approval, and ability to fund working capital requirements.

Future Outlook

The company plans to submit a request for an additional Type C meeting with the FDA to further discuss the design of a potential Phase 3 trial for govorestat in CMT-SORD, though the specific regulatory path, including accelerated approval, is yet to be determined. A meeting is also scheduled with the FDA in Q4 2025 to align on the regulatory path for govorestat in Classic Galactosemia, following a previous Complete Response Letter and warning letter. The company remains committed to advancing govorestat for CMT-SORD and is encouraged by new data for PMM2-CDG, supporting continued clinical development.

Management Comments

• "Our ongoing efforts in operational execution and regulatory progress have yielded important developments in the third quarter and beginning of the fourth quarter."
• "We completed a meeting with the FDA to discuss a potential NDA submission for govorestat for the treatment of CMT-SORD where we commenced constructive discussions as we continue to refine our regulatory strategy."
• "We expect to submit another meeting request with the FDA to further discuss the design of a potential Phase 3 trial."
• "We remain dedicated to advancing the development of govorestat for CMT-SORD patients and look forward to continued partnership with the FDA."
• "Simultaneously, we are scheduled to meet with the FDA in the fourth quarter to review govorestat for the treatment of classic galactosemia."
• "We were also encouraged by new data from a single patient with PMM2-CDG, a severe, rare, and debilitating disease, treated with govorestat."
• "We believe govorestats potential is underscored by a robust safety profile to date, with numerous patients across rare disease indications remaining on treatment for over four years."

Industry Context

Applied Therapeutics operates in the highly specialized and high-risk clinical-stage biopharmaceutical sector, focusing on rare diseases. The regulatory challenges highlighted for govorestat in CMT-SORD and Classic Galactosemia are typical for drug development, especially for novel treatments targeting rare conditions where endpoints and pathophysiology can be complex. The need for further FDA meetings and the previous Complete Response Letter for Classic Galactosemia underscore the stringent regulatory environment and the significant hurdles faced by companies in bringing new therapies to market. The positive single-patient data for PMM2-CDG, coupled with Orphan Drug and Rare Pediatric Disease designations, reflects the industry's focus on addressing unmet medical needs in small patient populations, often leveraging expedited pathways.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant uncertainty regarding the regulatory approval of key drug candidates and the company's ability to secure future funding could lead to share price volatility and dilution. The substantial cash burn is a major concern.
• Employees: Continued operational execution and regulatory progress are crucial for job security and morale, but the financial position and regulatory setbacks could create uncertainty.
• Patients (CMT-SORD, Classic Galactosemia, PMM2-CDG): The ongoing development and regulatory efforts for govorestat offer potential hope for transformative treatments, but the delays and regulatory hurdles mean a longer wait for approved therapies.
• FDA: Continued engagement with the company to provide guidance and feedback on regulatory pathways for rare disease treatments.

Next Steps

• Submit a request for an additional Type C meeting with the FDA to further discuss the design of a potential Phase 3 trial for govorestat in CMT-SORD.
• Attend a scheduled meeting with the FDA in Q4 2025 to align on the regulatory path forward for govorestat for Classic Galactosemia.
• Continue advancing the development of govorestat for patients with CMT-SORD.
• Continue clinical development for govorestat in PMM2-CDG.

Key Dates

Recommendation

The company faces critical financial and regulatory challenges. Cash reserves have plummeted to $11.9 million, indicating a severe cash burn rate that will necessitate a significant capital raise in the very near term, likely leading to substantial shareholder dilution. Furthermore, the regulatory path for its lead drug candidate, govorestat, is highly uncertain for its two primary indications: CMT-SORD has "key open issues" with the FDA requiring further meetings and an undetermined path to NDA, while Classic Galactosemia previously received a Complete Response Letter and warning letter. These regulatory setbacks, combined with the precarious financial position, suggest a high risk of further value erosion for investors.

Keywords

Applied Therapeutics, APLT, Biopharmaceutical, Rare Diseases, Govorestat, CMT-SORD, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, Classic Galactosemia, PMM2-CDG, Phosphomannomutase 2-Congenital Disorder Glycosylation, FDA, Type C Meeting, NDA, Clinical Trial, Financial Results, Q3 2025, Net Loss, Cash Burn, Board Resignation, Aldose Reductase Inhibitor